Ann Arbor Stage IV Hodgkin Lymphoma
5 clinical trials · Condition
◉ Watch Ann Arbor Stage IV Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma (NCT02758717) | Academic and Community Cancer Research United | 2016-05-13 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (NCT01771107) | National Cancer Institute (NCI) | 2013-03-08 |
Track Ann Arbor Stage IV Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.